Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Nycomed AS

Division of Takeda Pharmaceutical Co. Ltd.
www.takedanycomed.no

Latest From Takeda Nycomed AS

Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission

Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.

Deals M & A

Norway’s Pre Diagnostics Has Alzheimer’s Test In Its Sights

Pre Diagnostics AS is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis.

Medical Device Europe

Verona Adds Two Board Members

Verona Pharma plc, a drug development company focused on respiratory diseases, has appointed Ken Cunningham and Dr. Anders Ullman to its board of directors as non-executive directors – effective Sep. 10, 2015.

Respiratory Companies

Deal Watch: Merck’s Next Move In Cancer Immunotherapy Is BET Inhibitor, Bispecifics Gaining Steam

Pfizer pays Opko $295 million up front for global rights to develop and commercialize a long-acting recombinant human growth hormone, Roche and Novo Nordisk buy into bispecific technology and Janssen signs on with Halozyme, as Pfizer did two years earlier, to use the ENHANZE delivery platform technology with its own candidates against five targets.

BioPharmaceutical Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register